Stock listing

Hanover:ON4 ONO Pharmaceutical Co., Ltd. Aktie

German listing (Hanover) of ONO Pharmaceutical Co., Ltd. · home listing Tokyo:4528

Follow ONO Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.

ONO Pharmaceutical Co., Ltd. logo
Ticker
Hanover:ON4
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Hanover
Currency
EUR

What changed lately

Latest news

ONO Pharmaceutical: Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN Countries

Oct 8, 2026

Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN

Oct 8, 2026

ONO Pharmaceutical: Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the Treatment of Patients with Partial-onset Seizures, With or Without Secondary Generalized Seizures

Sep 16, 2026

Kaneka Ubiquinol™ memenangi nutraingredients Asia Ingredient of the Year: healthspan Award 2026

Sep 8, 2026

Issued by another party

OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO

Aug 19, 2026

ONO Pharmaceutical: Continues to be Selected for ESG Investment Indexes Adopted by GPIF

Aug 17, 2026

Consolidated Financial Results for the First Quarter of Fiscal Year Ending March 31, 2027 (IFRS)

Jul 30, 2026

Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation

Jul 9, 2026

ONO Pharmaceutical: Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement of Malignant Lymphoma in Patients with Inadequate Response to Existing Therapies or in Whom Such Therapies Are Not Appropriate

Jun 11, 2026

ONO Pharmaceutical: Pharma Announces Oral Presentation of New Data from Phase 2 Clinical Study of -4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting

Jun 1, 2026

All ONO Pharmaceutical Co., Ltd. news

Decks

ONO Pharmaceutical Co., Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
31 in the last 12 months · 38 in all · newest Oct 8, 2026 · oldest 2025
Decks
38 decks · latest Jul 31, 2026

Where ONO Pharmaceutical Co., Ltd. is listed

ListingExchangeCountryCurrency
Tokyo:4528 小野薬品工業 · Home listingTokyoJapanJPY
OTC:OPHLYOTCUnited StatesUSD
LS Exchange:859650LS ExchangeGermanyEUR
Lang & Schwarz:859650Lang & SchwarzGermanyEUR
BMV:4528NBMVMexicoMXN
gettex:ON4gettexGermanyEUR
OTC:OPHLFOTCUnited StatesUSD
Dusseldorf:ON4DusseldorfGermanyEUR
Frankfurt:ON4FrankfurtGermanyEUR
BIVA:4528NBIVAMexicoMXN
gettex:ON40gettexGermanyEUR
Lang & Schwarz:A2N6NCLang & SchwarzGermanyEUR
Munich:ON4MunichGermanyEUR
Munich:ON40MunichGermanyEUR
Stuttgart:ON4StuttgartGermanyEUR
Tradegate:ON4TradegateGermanyEUR
Hamburg:ON4HamburgGermanyEUR
Hanover:ON4 · This pageHanoverGermanyEUR

Log in to ask 6ix AI your own questions about ONO Pharmaceutical Co., Ltd.